C4 Therapeutics (CCCC) EBIT Margin: 2019-2025
Historic EBIT Margin for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to -306.43%.
- C4 Therapeutics' EBIT Margin fell 12257.00% to -306.43% in Q3 2025 from the same period last year, while for Sep 2025 it was -431.07%, marking a year-over-year decrease of 7663.00%. This contributed to the annual value of -336.15% for FY2024, which is 33369.00% up from last year.
- C4 Therapeutics' EBIT Margin amounted to -306.43% in Q3 2025, which was up 30.51% from -440.99% recorded in Q2 2025.
- In the past 5 years, C4 Therapeutics' EBIT Margin registered a high of -75.98% during Q4 2021, and its lowest value of -1,410.21% during Q2 2023.
- Moreover, its 3-year median value for EBIT Margin was -440.99% (2025), whereas its average is -643.11%.
- As far as peak fluctuations go, C4 Therapeutics' EBIT Margin crashed by 126,575bps in 2022, and later soared by 123,162bps in 2024.
- C4 Therapeutics' EBIT Margin (Quarterly) stood at -75.98% in 2021, then plummeted by 126,575bps to -1,341.73% in 2022, then skyrocketed by 19,402bps to -1,147.72% in 2023, then surged by 41,932bps to -728.39% in 2024, then slumped by 12,257bps to -306.43% in 2025.
- Its EBIT Margin was -306.43% in Q3 2025, compared to -440.99% in Q2 2025 and -402.93% in Q1 2025.